Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/18/2017 01/19/2017 01/20/2017 01/23/2017 01/24/2017 Date
362.95(c) 363.41(c) 362.56(c) 354.36(c) 347.96 Last
473 967 586 322 781 954 899 779 905 380 Volume
-0.08% +0.13% -0.23% -2.26% -1.81% Change
More quotes
Financials ($)
Sales 2016 4 928 M
EBIT 2016 1 856 M
Net income 2016 892 M
Finance 2016 834 M
Yield 2016 -
Sales 2017 5 732 M
EBIT 2017 2 323 M
Net income 2017 1 143 M
Finance 2017 1 338 M
Yield 2017 -
P/E ratio 2016 45,94
P/E ratio 2017 36,62
EV / Sales2016 7,42x
EV / Sales2017 6,29x
Capitalization 37 374 M
More Financials
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company.It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.The company involves in marketing medicines for eye diseases, colorectal cancer and a rare inflammatory... 
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
06:02p REGENERON PHARMACEUTICALS : Forty of Nation's Brightest Young Scientists Named R..
06:01p REGENERON PHARMACEUTICALS : Forty of Nation's Brightest Young Scientists Named R..
09:15a REGENERON PHARMACEUTICALS : The Hartford Investment Management Co. Sells 315 Sha..
01/23 REGENERON PHARMACEUTICALS : Biotech Stocks Under Scanner -- Kite Pharma, BioPhar..
01/12 REGENERON PHARMACEUTICALS : Findings from Regeneron Pharmaceuticals Provide New ..
01/12 REGENERON PHARMACEUTICALS : Hires Jay Markowitz, M.D., as Senior Vice President ..
01/10 REGENERON PHARMACEUTICALS,INC. (NASD : REGN) Files An 8-K Results of Operations ..
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09 REGENERON PHARMACEUTICALS INC : Results of Operations and Financial Condition, R..
01/09 SANOFI : and Regeneron to Appeal U.S. District Court Rulings in Ongoing Patent L..
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
Latest Tweets
03:01pWe're Hesitant On AnaptysBio's IPO  
01/23Healthcare Summit On The Eve Of Trump's New Deal: Milligan's Mea Culpa
1
01/22Regeneron Pharmaceuticals's hold rating reiterated at JPMorgan Chase & Co.. 
01/20Largest gainers on my Watch List today were: $GWR $COF $MIDD $ALXN $REGN  
01/19Reasons A Regeneron Pharmaceuticals Takeover Is Unlikely  
More tweets
Qtime:75
News from SeekingAlpha
09:14a BIOTECHNOLOGY : Can Trump Be A Catalyst?
09:01a We're Hesitant On AnaptysBio's IPO
01/23 HEALTHCARE SUMMIT ON THE EVE OF TRUM : Milligan's Mea Culpa
01/20 Implications Of The Latest Smash In Bristol-Myers Squibb Stock
01/19 Reasons A Regeneron Pharmaceuticals Takeover Is Unlikely
Advertisement
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 435 $
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
George Damis Yancopoulos President & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
Charles A. Baker Independent Class III Director
Michael S. Brown Independent Class I Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTIC..-3.47%37 374
AMGEN, INC.4.45%113 612
GILEAD SCIENCES, INC.-1.28%93 131
CELGENE CORPORATION-2.97%87 063
ACTELION LTD1.18%24 865
VERTEX PHARMACEUTICALS..10.49%20 190
More Results